中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
19期
2976-2978
,共3页
心力衰竭,充血性%细胞因子类%卡维地洛
心力衰竭,充血性%細胞因子類%卡維地洛
심력쇠갈,충혈성%세포인자류%잡유지락
Heart failure,congestive%Cytokines%Carvedilol
目的 探讨卡维地洛对慢性充血性心力衰竭(CHF)患者血浆炎性细胞因子及临床疗效的影响.方法 选择住院治疗CHF患者72例,采用随机数字表将患者分为观察组与对照组.两组患者入院后予以强心、利尿和扩张血管等常规治疗.观察组患者在此基础上加用卡维地洛治疗,初始剂量3.125 ag,2次/d,逐渐递增加量,直至维持量25mg,2次/d,连用12周.观察比较两组治疗前后血浆肿瘤坏死因子-α(TNF-α)、白细胞介素-1(IL-1)和白细胞介素-6(IL-6)水平变化及临床治疗效果.结果 治疗12周后,两组血浆TNF-α、IL-1和IL-6均较前明显下降(t=3.02、3.17、2.97、2.26、2.25、2.21,均P＜0.05),且观察组下降幅度较对照组更显著(t =2.32、2.35、2.29,均P＜0.05)；同时观察组的临床总有效率(94.44％)明显高于对照组(77.78％)(x2 =4.18,P＜0.05),两组患者治疗期间未见明显的药物不良反应.治疗后随访1年,观察组再次住院率(61.11％)明显低于对照组(36.11％)(x2=4.50,P＜0.05),但两组病死率差异无统计学意义(x2=0.26,P＞0.05).结论 卡维地洛治疗CHF安全有效,能降低血浆细胞因子TNF-α、IL-1和IL-6水平,减少患者的再次住院率,改善患者的预后.
目的 探討卡維地洛對慢性充血性心力衰竭(CHF)患者血漿炎性細胞因子及臨床療效的影響.方法 選擇住院治療CHF患者72例,採用隨機數字錶將患者分為觀察組與對照組.兩組患者入院後予以彊心、利尿和擴張血管等常規治療.觀察組患者在此基礎上加用卡維地洛治療,初始劑量3.125 ag,2次/d,逐漸遞增加量,直至維持量25mg,2次/d,連用12週.觀察比較兩組治療前後血漿腫瘤壞死因子-α(TNF-α)、白細胞介素-1(IL-1)和白細胞介素-6(IL-6)水平變化及臨床治療效果.結果 治療12週後,兩組血漿TNF-α、IL-1和IL-6均較前明顯下降(t=3.02、3.17、2.97、2.26、2.25、2.21,均P＜0.05),且觀察組下降幅度較對照組更顯著(t =2.32、2.35、2.29,均P＜0.05)；同時觀察組的臨床總有效率(94.44％)明顯高于對照組(77.78％)(x2 =4.18,P＜0.05),兩組患者治療期間未見明顯的藥物不良反應.治療後隨訪1年,觀察組再次住院率(61.11％)明顯低于對照組(36.11％)(x2=4.50,P＜0.05),但兩組病死率差異無統計學意義(x2=0.26,P＞0.05).結論 卡維地洛治療CHF安全有效,能降低血漿細胞因子TNF-α、IL-1和IL-6水平,減少患者的再次住院率,改善患者的預後.
목적 탐토잡유지락대만성충혈성심력쇠갈(CHF)환자혈장염성세포인자급림상료효적영향.방법 선택주원치료CHF환자72례,채용수궤수자표장환자분위관찰조여대조조.량조환자입원후여이강심、이뇨화확장혈관등상규치료.관찰조환자재차기출상가용잡유지락치료,초시제량3.125 ag,2차/d,축점체증가량,직지유지량25mg,2차/d,련용12주.관찰비교량조치료전후혈장종류배사인자-α(TNF-α)、백세포개소-1(IL-1)화백세포개소-6(IL-6)수평변화급림상치료효과.결과 치료12주후,량조혈장TNF-α、IL-1화IL-6균교전명현하강(t=3.02、3.17、2.97、2.26、2.25、2.21,균P＜0.05),차관찰조하강폭도교대조조경현저(t =2.32、2.35、2.29,균P＜0.05)；동시관찰조적림상총유효솔(94.44％)명현고우대조조(77.78％)(x2 =4.18,P＜0.05),량조환자치료기간미견명현적약물불량반응.치료후수방1년,관찰조재차주원솔(61.11％)명현저우대조조(36.11％)(x2=4.50,P＜0.05),단량조병사솔차이무통계학의의(x2=0.26,P＞0.05).결론 잡유지락치료CHF안전유효,능강저혈장세포인자TNF-α、IL-1화IL-6수평,감소환자적재차주원솔,개선환자적예후.
Objective To investigate the impact of carvedilol on plasma cytokines in patients with chronic congestive heart failure(CHF) and its efficacy analysis.Methods 72 hospitalized patients with CHF were randomly divided into observation group and control group.The two groups were given standard therapy after admission.The observation group were given addition of carvedilol with an initial dose of 3.125mg,2 times daily,gradually increasing amount until the maintenance dose of 25mg,2 times daily for 12 weeks.Results After 12 weeks of treatment,plasma TNF-α,IL-1 and IL-6 in both groups were significantly decreased than before (t =3.02,3.17,2.97,2.26,2.25,2.21,all P ＜ 0.05) and the decline in the observation group was more significant than those in the control group(t =2.32,2.35,2.29,all P ＜ 0.05);The total clinical efficiency in the observation group(94.44％) was significantly higher(77.78％)(x2 =4.18,P ＜ 0.05),and there were no significant adverse drug reactions during treatment in both groups.During 1-year follow-up after treatment,re-hospitalization rate in the observation group (61.11％) was significantly lower than that in the control group (36.11％) (x2 =4.50,P ＜ 0.05),but there was no statistically significant difference in mortality between two groups (x2 =0.26,P ＞ 0.05).Conclusion Carvedilol is a safe and effective drug for the treatment of CHF,which can lower plasma cells factor TNF-α,IL-1 and IL-6 levels,reduce patient re-hospitalization rates,and help to improve the patients' prognosis.
